Tin tức & Cập nhật
Xem bài viết Nội tiết
Xem
Chỉ hiển thị Multimedia

Liraglutide boosts lipid metabolism in T2DM, but comes with more side effects
02 Sep 2022
Compared with dapagliflozin, the glucagon-like peptide 1 liraglutide induces better lipid metabolism in patients with type 2 diabetes mellitus (T2DM), a recent study has found. However, this drug also comes with more adverse events than its sodium-glucose co-transporter 2 inhibitor comparator.
02 Sep 2022

Vitamin D3 supplementation safe, well tolerated in overweight/obese prediabetics
02 Sep 2022
bởiStephen Padilla
Taking vitamin D3 supplementation at 4,000 IU per day does not produce any safety concern and is well tolerated among overweight and obese participants who are at risk for diabetes, reports a study.
02 Sep 2022

Latest glucose-lowering drug use and glycaemic outcome trends in HK
30 Aug 2022
bởiNatalia Reoutova
A retrospective cross-sectional analysis of trends in glucose-lowering drug (GLD) use and glycaemic outcomes among Hong Kong’s 0.9 million adults with diabetes between 2002 and 2019 finds a levelling off in improvements since 2014.
30 Aug 2022






